PATENT CLAIM ANALYSIS

Application Number: 15761725
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-12
Patent Classification: ["514", "017800"]

Abstract:
The present invention relates to an agent which inhibits Kallikrein-8 for use in the treatment or prevention of Alzheimer's disease and/or its precursor stages, as well as to methods, kits and uses relating thereto, including diagnostic tools.

Claim (Index 6):
An agent for use according to any of  claims 1  to  5 ,\n (1) wherein the agent is administered to a patient\n (a) who has Alzheimer's disease and/or a preclinical stage of Alzheimer's disease or a precursor stage of Alzheimer's disease, \n and/or \n (b) is diagnosed to have Alzheimer's disease and/or a precursor stage of Alzheimer's disease or a preclinical stage of Alzheimer's disease, \n and/or \n (c) is identified to be responsive to treatment with an agent which inhibits Kallikrein-8, preferably wherein the patient is identified to have an increased level of Kallikrein 8 and/or kallikrein 8 mRNA in at least one bodily sample and/or in at least one bodily tissue, \n preferably wherein the patient has Alzheimer's disease and/or a precursor stage of Alzheimer's disease or a preclinical stage of Alzheimer's disease at the start of treatment, and/or \n is diagnosed to have Alzheimer's disease and/or a precursor stage of Alzheimer's disease or a preclinical stage of Alzheimer's disease at the start of treatment, \n more preferably wherein the patient has Alzheimer's disease and/or a preclinical stage of Alzheimer's disease, in particular at the start of treatment, and/or \n is diagnosed to have Alzheimer's disease and/or a preclinical stage of Alzheimer's disease, in particular at the start of treatment, \n \n and/or \n (2) wherein administration to a patient results in reduced amyloidogenic APP processing and/or reduced A\u03b2 load and/or reduced Tau hyperphosphorylation and/or a decreased proportion of neuritic plaques and/or improved neurovascular function and/or improved A\u03b2 clearance across the blood-brain-barrier, and/or enhanced autophagy and/or enhanced microglial A\u03b2 phagocytosis, \n and/or \n (3) wherein prevention of Alzheimer's disease and/or of a precursor stage of Alzheimer's disease is attenuating the severity or delaying the onset of at least one clinical symptom of the Alzheimer's disease or of a precursor stage of Alzheimer's disease, in particular increased anxiety and/or cognitive impairment, \n and/or \n (4) wherein treatment of Alzheimer's disease and/or of a precursor stage of Alzheimer's disease is mitigation of at least one symptom of Alzheimer's disease, and/or of a precursor stage of Alzheimer's disease, in particular mitigation of increased anxiety and/or cognitive impairment, \n and/or \n (5) wherein the agent which inhibits Kallikrein-8 inhibits proteolytic fragmentation by Kallikrein-8 of at least one protein comprising the sequence YGRY (SEQ ID No: 1), preferably wherein the at least one protein is selected from EPHB2, steroid 5 alpha-reductase 1, casein, fibronectin, collagen type IV, fibrinogen, kininogen, neuregulin-1, CAM-L1, single-chain tPA, PAR2, pro-KLK1 and pro-KLK11.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 90.0
- Lexical Diversity: 1.10526
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12157664', '13393220', '14324289', '13701758', '11185907']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7565896997530215
- 35 USC 102 Novelty (BERT): 0.5236638526954778
- Combined Prediction Score: 0.7332971150472671
- Mean Citation Score: 308.592442
- Max Citation Score: 328.3323
- Similarity Product: 220.0951551576376

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test